SEPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Septerna Inc (SEPN) is not a strong buy for a beginner investor with a long-term focus at this time. While the stock has shown positive momentum and analysts have raised price targets, insider selling and negative financial performance trends suggest caution. Additionally, there are no significant recent news catalysts or proprietary trading signals to justify immediate action.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 60.852, and moving averages are converging, suggesting no strong trend. The stock is trading near its resistance level (R1: 25.042), with limited upside potential in the short term.
Analysts have raised price targets recently, with JPMorgan, Truist, and H.C. Wainwright maintaining Buy or Overweight ratings. Positive Phase 1 trial data for SEP-631 has increased the probability of approval for the drug.
Insiders are selling heavily, with a 1608.82% increase in selling activity over the last month. Financial performance in Q4 2025 showed a significant drop in net income (-48.05% YoY) and EPS (-61.90% YoY). No recent news or congress trading data to support bullish sentiment.
In Q4 2025, revenue increased significantly by 11276.42% YoY to $24.12M, but net income dropped to -$10.74M (-48.05% YoY), and EPS declined to -0.24 (-61.90% YoY). Gross margin remained stable at 100%.
Analysts are bullish, with recent upgrades in price targets: JPMorgan to $38, Truist to $35, and H.C. Wainwright to $40. The updates reflect optimism about clinical trial progress and potential drug approval.
